Udenafil

Unassigned

New Medicines

Congenital heart disease after fontan palliation in adolescents

Information

New molecular entity
Mezzion
Mezzion

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

A small-molecule, pyrazolopyrimidinone derivative that inhibits type 5 cyclic nucleotide phosphodiesterase.
Congenital heart disease is one of the most common types of birth defect, affecting up to 8 in every 1,000 babies born in the UK. Operative mortality of the Fontan procedure has steadily decreased and is currently <2% [1].
Congenital heart disease after fontan palliation in adolescents
Oral

Evidence based evaluations